RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)

Clinical trials for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope pill tested for tough blood cancers

Disease control Not yet recruiting

This is a first-in-human study testing a new oral medication called APG-3288 for people with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will al…

Matched conditions: RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)

Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control

Last updated Mar 16, 2026 15:24 UTC

RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)

Get alerted when new RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) trials appear

New hope pill tested for tough blood cancers